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Theassociationbetween non-Hodgkinlymphomasandautoimmunedisordersisawell-knownevent.Alsoautoimmunehemolytic
anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this
groupofpatients.Inrecent years,amongthemoretraditionaltherapeutic options,rituximab,ananti-CD20monoclonalantibody,
has shown interesting results in the treatment of primary AHA. Although this drug has been frequently used for AHA in patients
with CLL, much less data are available on its use in NHL patients. However, considering that the main pathogenetic mechanism
of AHA in course of lymphoproliferative disorders seems to be an antibody production directly or indirectly mediated by the
neoplastic clone, this monoclonal antibody represents an ideal therapeutic approach. In this paper we will brieﬂy describe some
biological and clinical features of NHL-patients with AHA. We will then analyze some studies focusing on rituximab in primary
AHA, ﬁnally reviewing the available literature on the use of this drug in NHL related AHA.
1.AutoimmuneHemolyticAnemiain
Non-Hodgkin Lymphomas
The association between lymphomagenesis and autoim-
munity is a well-known scenario mainly derived from
reports describing both patients and mouse strains in
which autoimmune manifestations and lymphoproliferative
disorders coexisted [1]. On the other hand in recent years
population-basedstudieshavespeciﬁcally shown thatseveral
autoimmune disorders are associated with an increased
risk in developing non-Hodgkin lymphomas (NHL) [2,
3]. Some factors have been speciﬁcally advocated as pos-
sible explanations for this association, such as chronic
immune stimulation, immunomodulating drugs, and com-
mon genetic or environmental variables. Lymphomagenesis
and autoimmunitycouldbe pathogeneticallyputtogetherby
considering that both of them result from the impairment of
the physiologic mechanisms which should control lymphoid
cell growth and diﬀerentiation [4].
Autoimmune hemolytic anemia (AHA), although much
more frequent in patients with chronic lymphocytic
leukemia [5], has been described also in a small proportion
of NHL, patients, ranging from 3 to 6% in diﬀerent
cohorts [6, 7]. Besides several anecdotal reports [8], clinical
and prognostic features of patients with AHA have been
investigated in a large cohort of NHL patients. In this study
16 subjects (3%) with AHA have been selected among 517
NHL patients. Ten patients had B-cell NHL, 5 T-cell NHL
and 1 poorly diﬀerentiated NHL while follicular lymphoma
was the most represented subtype, having being diagnosed
in 5 subjects. While looking at diﬀerent subtypes of AHA
warmandcoldantibodieswereidentiﬁedin13and3patients
respectively. Patients with AHA were more likely to have
T-cell NHL when compared to the whole cohort (33%
versus 14%). A signiﬁcantly higher proportion of patients
with NHL-associated AHAwere diagnosed with monoclonal
gammopathy (8%versus25%).MoreoverpatientswithAHA
showed a trend towards a worse response rate to antilym-
phoma treatments and were apparently characterized by a
reduced overall survival, although one may speculate that
thisﬁnding representsjustasurrogate oftheworse prognosis
correlated to both T-cell phenotype and paraproteinemia.
Finally, in most patients a discrepancy among time to
response of NHL and AHA was observed, thus suggesting2 Advances in Hematology
possible diﬀerent pathways mediating response to treatment
[6].
In another series evaluating 370 NHL patients AHA was
detectedin23patients(6.2%),19withwarm-typeand4with
cold-type antibodies. This report then focused on the 4 cases
with cold agglutinin disease (CAD), showing then that all of
them were having low-grade NHL and had monoclonal IgM
gammopathy. In 3 of them both NHL and AHA showed a
good response to chlorambucil plus prednisone [7].
A somehow specular point of view has been recently
oﬀered by the above-mentioned case population study on
patients with autoimmune manifestations, which showed
that even AHA, although much less than other autoimmune
diseases, is associated with a 2.6-fold increase in NHL risk.
This association is even more evident among subjects with
longAHAdurationand isstrongerforB-cellNHL,especially
for the diﬀuse large B-cell lymphoma subtype [2]. Another
report has also suggested that AHA could be preferentially
associated with other NHL subtypes, such as marginal zone
NHL and T-cell lymphomas [3].
2.RituximabinPrimaryAutoimmune
HemolyticAnemia
In recent years, among the more traditional therapeutic
options, such as steroids and other immunomodulating
drugs, also monoclonal antibodies have become available for
the treatment of AHA. Apart from limited experiences with
alemtuzumab [9], rituximab has shown the most interesting
results. This monoclonal antibody is directed against the
C D 2 0a n t i g e ne x p r e s s e do nB - l y m p h o c y t e sa n di sw i d e l y
used in thetreatment oflymphoproliferativedisorders. More
in details, it has been nowadays incorporated in the ﬁrst line
treatment of both indolent [10] and aggressive NHL [11],
having oﬀered in both conditions a marked improvement in
terms of response rates and overall survival.
In the preliminary studies on the use of rituximab on
AHA, after the ﬁrst report on a child with AHA associated to
pure red cell aplasia successfully treated with rituximab and
intravenous immunoglobulins [12], 13 out of 15 children
with warm antibody AHA showed responses to rituximab
[13]. On the other hand, it was also highlighted as in 4
patients with Evan’s syndrome either immune thrombocy-
topenia or AHA only responded, but not both [14].
Besides several case reports, in recent years three
manuscripts have focused on larger patient cohorts. D’Arena
and colleagues described the use of rituximab in warm-
type idiopathic AHA. All patients were refractory to
steroids and/or immunosuppressive drugs and all were given
weekly rituximab 375mg/m2 for four consecutive weeks. An
increase in hemoglobin levels was observed in all cases, with
a mean increment of 3.3g/dL. At a mean followup of 604
days, 8 patients were still in complete remission and 3 in
partial remission [15]. Recently, the eﬀects of 68 courses of
rituximab in 53 Belgian patients with AHA were reported.
All patients were given rituximab after failing at least one
previous line of treatment, including splenectomy in 19%
of them. Overall response rates were 79%, with a median
followup since ﬁrst rituximab administration of 15 months.
Progression-free survival at 1 and 2 years was 72% and 56%
respectively [16]. The eﬃcacy and safety of rituximab was
also evaluated in a retrospective study including 27 adults
withwarm antibody AHArefractory to severalpreviouslines
of therapy. Overall, 8 patients achieved a complete response
and 17 a partial response. After a mean followup of 21
months, 5 patients relapsed and 3 of them were successfully
retreated with rituximab [17].
3.Use of Rituximab in Autoimmune Hemolytic
Anemia Associatedwith
Non-Hodgkin Lymphomas
The rational of using rituximab in NHL patients expe-
riencing AHA is dual. First of all, as above mentioned,
this drug has been demonstrated to play a relevant
role in the treatment of primary AHA, having been
widely tested in patients refractory to previous line of
treatment [12–17]. Moreover, as the main pathogenetic
mechanism of NHL related AHA seems to be an anti-
body production directly or indirectly mediated by the
neoplastic clone [18, 19], exploiting a well-demonstrated
antilymphoma treatment is undoubtedly an intriguing
strategy.
Ten years ago, rituximab has been frequently employed
in AHA occurring in chronic lymphocytic leukemia (CLL)
[30], and its use has been recently incorporated in the
guidelines from the International Workshop on CLL [31].
The experience in using rituximab in NHL patients with
AHA is much less robust and so far, besides some reports
on patients with concomitant CAD and lymphoproliferative
disorders [32–34], ten single cases have been reported
between 1998 and 2009 [20–29], as shown in Table 1.T h e
more frequent histological patterns are lymphoplasmacytic
[22–24] and marginal zone NHL [20, 25–27, 29], described
in 4 and 5 cases respectively. A patient with splenic T-
cell angioimmunoblastic NHL has been also described,
representing the only reported case in which rituximab was
unsuccessful [28]. In 6 out of 10 cases, cold agglutinins
were detected while mixed and warm autoantibodies were
present in 1 and 3 cases, respectively. All the patients were
refractory to at least one previous treatment and 5 out
of the 9 patients who then responded to rituximab had
previously received three or more lines of treatment. In most
cases rituximab was administered at a dose of 375mg/m2
weeklyforfourweeks,sometimes inassociation withsteroids
or other medications. In all the reported case, with the
exception of the splenic T-cell angioimmunoblastic NHL, a
complete remission of AHA occurred within the ﬁrst month
from the ﬁrst rituximab administration and responses were
usually long lasting. As most of these case reports describe
patients with indolent NHL, in which disease eradication
is usually not a primary goal of the treatment, the degree
of response of the lymphoproliferative disorders to ritux-
imab was usually not reported. Interestingly a patient with
small lymphocyte NHL who developed severe hemolytic
anaemia due to posttransfusional alloimmunization, was
very recently reported to respond to a rituximab-based
immunochemotherapy [35]. The eﬃcacy of rituximab wasAdvances in Hematology 3
Table 1: Reported cases of non-Hodgkin lymphoma-associated autoimmunehemolytic anemia treated with rituximab.
First author and year of
publication NHL subtype Antibodies Response to
rituximab Previous treatments
Lee and Kueck 1998 [20] Marginalzone Cold Yes Steroids, cyclophosphamide,plasma exchange
Bauduer 2001 [21] Lymphoplasmacytic Cold Yes Steroids, cyclophosphamide,cyclosporine, plasma exchange
Cohen et al. 2001 [22] Lymphoplasmacytic Cold Yes Steroids
Layios et al. 2001 [23] Lymphoplasmacytic Cold Yes Steroids, cyclophosphamide,plasma exchange, vincristine
Mori et al. 2002 [24] Lymphoplasmacytic Cold Yes Steroids, splenectomy, chop
Paydas et al. 2003 [25] Marginalzone Warm Yes Steroids
Petit et al. 2003 [26] Marginalzone Cold Yes Steroids, chlorambucil
Fabbri et al. 2006 [27] Marginal zone Warm Yes Steroids, splenectomy, cvp
Win et al. 2007 [28] Splenic T-cell
angioimmunoblastic Mixed No Steroids, intravenousImmunoglobulin,chemotherapy
Fozza et al. 2009 [29] Marginalzone Warm Yes Steroids
Abbreviations: CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone/prednisolone); CVP (cyclophosphamide, vincristine, prednisone/
prednisolone); NHL (non-Hodgkin lymphoma).
also reported in a case in which both an aggressive form of
multicentric Castleman disease and AHA responded [36].
As above mentioned, some reports evaluated the eﬃcacy
of rituximab in patients with CAD, some of which had
concomitant lymphoproliferative disorders. Berentsen and
colleaguesreported aboutthe use ofrituximab in the context
of a population-based clinical study of 86 patients with
primary chronic CAD,76% of which had concomitantNHL.
Thirty-three patients had lymphoplasmacytic lymphoma,
5 marginal zone lymphoma, 4 small lymphocytic B-cell
lymphoma or, CLL and 8 undeﬁned clonal lymphocytosis.
Insuchacontextrituximabwastheonlysuccessful approach,
showing response rates around60%,apparentlynondiﬀerent
among patients suﬀering or not from NHL [32]. The same
group reported on 37 courses of rituximab monotherapy
administered within a prospective trial to 27 patients with
primary CAD,19 of which with concomitant NHL. Fourteen
o ft h e2 7p a t i e n t sr e s p o n d e dt ot h eﬁ r s tc o u r s eo fr i t u x i m a b
showing 1 complete and 13 partial remissions, according
to the response criteria deﬁned in the study. Eight patients
relapsed and were retreated with rituximab, in some patients
associated with interferon, resulting in 5 partial remissions.
On the whole, responses were achieved after 20 of 37 courses
ofrituximab.Median timetoresponse was1.5months, while
medianincreaseinhemoglobinlevelwas4.0g/L.Themedian
response duration was 11 months and all butone responders
observed for more than 12 months relapsed [33]. Slightly
lower response rates have been reported in a prospective
study of 20 patients with chronic CAD, 7 of which had
lymphoproliferative disorders [34].
In conclusion, although it should be noted that patients
unsuccessfully treated with rituximab are much less likely to
be reported, the analysis of the available literature suggests
that this monoclonal antibody represents a valid therapeutic
option in the treatment of AHA in NHL patients. Keeping in
mindthatahighproportionofpatientsrelapseafteraninitial
response to rituximab, it remains to be determined if this
drug may play a role even in the maintenance. Considering
both the pathogenetic mechanisms underlying AHA in NHL
patients as well as the poor response rates oﬀered by other
therapeutic alternatives, we conclude that rituximab can be
considered a valid strategy in NHL patients with steroid
refractory AHA as well as a possible option for ﬁrst-line
treatment in selected cases.
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